More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback Million Hearts
CMS 'Million Hearts' CVD Risk Reduction Model Works
https://www.medscape.com/viewarticle/997551
- RCT JAMA - https://jamanetwork.com/journals/jama/fullarticle/2810696
AC in ICH - ENRICH AF
Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547
- Lancet Neurology Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0
- ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1
II. TAVI vs SAVR
Low-Risk TAVR Studies: Divergent Long-Term Results
https://www.medscape.com/viewarticle/997784
- Partner 3 Main Results
- Partner 3 – Five Year
- Original EVOLUT -LR https://www.nejm.org/doi/10.1056/NEJMoa1816885
- EVOLUT 3-year https://doi.org/10.1016/j.jacc.2023.02.017
- EVOLUT -LR 4-year https://doi.org/10.1016/j.jacc.2023.09.813
III. Myocardial Viability
Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2
https://www.medscape.com/viewarticle/989101
- Revived BCIS – Original paper https://www.nejm.org/doi/10.1056/NEJMoa2206606
- JAMA Cardiology Viability paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2810727
- STICH Viability Paper - https://www.nejm.org/doi/full/10.1056/NEJMoa1100358
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net